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Abstract: Rheumatoid arthritis (RA) is a systemic, chronic and inflammatory disease of unknown etiology with genetic 
predisposition. The advent of new biological agents, as well as the more traditional disease-modifying antirheumatic 
drugs, has resulted in highly efficient therapies for reducing the symptoms and signs of RA; however, not all patients 
show the same level of response in disease progression to these therapies. These variations suggest that RA patients may 
have different genetic regulatory mechanisms. The extensive polymorphisms revealed in non-coding gene-regulatory re-
gions in the immune system, as well as genetic variations in drug-metabolizing enzymes, suggest that this type of varia-
tion is of functional and evolutionary importance and may provide clues for developing new therapeutic strategies. Phar-
macogenetics is a rapidly advancing area of research that holds the promise that therapies will soon be tailored to an indi-
vidual patient’s genetic profile. 
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INTRODUCTION 
  Rheumatoid arthritis (RA) is a chronic, systemic and in-
flammatory joint disease that leads to bone and cartilage 
destruction, as well as a wide variety of extra-articular mani-
festations. The hyperplastic synovial membrane mediates 
this process by invading deeply into articular cartilage and 
bone. During this process, a variety of both inflammatory 
and noninflammatory mediators, including proinflammatory 
cytokines, such as interleukin-1 (IL-1) and tumor necrosis 
factor- (TNF-), the metalloproteinases (MMPs), CD4+ 
cells, B lymphocytes, macrophages and synovial fibroblasts, 
contribute to the pathogenesis of RA. 
  Although well proven, the efficacy of the new drugs used 
to treat RA is variable. While there are no useful and reliable 
clinical or molecular markers for response to therapy, the 
levels of various cytokines and other mediators of inflamma-
tion may correlate with the efficacy of the therapies. The 
main focus of pharmacogenetics up to the present has been 
on the study of drug-metabolizing enzymes but polymor-
phisms in drug targets as well as transporters are now also 
under investigation [1].  
  In this review, we report the clinical influence of some of 
the gene polymorphisms associated with RA and the princi-
ples of pharmacogenetics applied to different therapies, such 
as classical disease-modifying antirheumatic drugs (DMA- 
RDs) and the new biological agents. In the near future, 
pharmacogenetic studies may make it possible to precisely 
select medications and dosages for individual patients [1].  
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CLINICAL INFLUENCE OF GENE POLYMOR-
PHISMS IN RA 
  Many diseases are multifactorial; both environmental and 
genetic factors contribute to etiology and/or clinical severity. 
The genetics of many multifactorial diseases is complex, 
involving multiple genes. Mendelian patterns of inheritance 
often do not apply. The genetic contribution to susceptibility 
for RA is demonstrated by family clustering and a three-fold 
to four-fold higher pair-wise concordance percentage for 
clinically expressed RA in monozygotic twins compared to 
dizygotic twins [2]. Estimates from several authors suggest 
that at least 10 different genetic regions may be related to 
RA [3]. The variability in the contribution of the multiple 
genetic factors involved in RA may be related to the variabil-
ity of severity seen in clinical presentation. The variability in 
response to drugs is similarly greater across the population 
than within the same patient or between monozygotic twins. 
Part of this difference is attributable to genetic factors [4]. 
  Most of the genes implicated in predisposition to RA are 
within the HLA-DR loci [5], however, these loci are not the 
only contributors. Other attractive candidates include the 
genes for cytokines. Cytokines are important mediators of 
the inflammatory response and play an important role in the 
pathophysiology of joint inflammation and destruction in RA 
[6]. 
The HLA Complex 
  One genetic region consistently shown to be associated 
with RA is the Major Histocompatibility Complex (MHC). 
The contribution from this region is estimated to be as much 
as 30% of the total genetic effect [7]. RA is associated with 
specific HLA-DRB1 alleles that encode a conserved se-
quence of amino acids (residues 70-74 in the DR1 chain) 
known as the shared epitope (SE) [8]. This sequence is in the 382    Current Genomics, 2008, Vol. 9, No. 6  Rego-Pérez et al. 
peptide-binding groove. The alleles carrying this sequence 
are DRB1*0401, DRB1*0404, DRB1*0405, DRB1*0408, 
DRB1*0101, DRB1*0102 and DRB1*1001 [9]. The pres-
ence and gene dosage of HLA-DRB1 alleles encoding the 
SE have been associated with the presence of rheumatic 
nodules, a more rapid rate of development of erosions seen 
in radiography, vasculitis, Felty´s syndrome, and increased 
need for joint surgery [10]. Interestingly, the DRB1*0401/ 
*0404 genotype appears to be particularly associated with 
early disease onset and a more severe disease phenotype [9]. 
  DNA microsatellites in the HLA region have been de-
scribed. The HLA-B-associated transcript 2 (BAT2) and 
D6S273 are HLA class III microsatellites, whereas D6S2223 
is a HLA class I microsatellite marker [11]. In this review 
we´ll describe how some of these microsatellite markers 
have been shown to be associated with the response to thera-
pies. 
Cytokine Genes in RA 
  Considering the critical role that several cytokines, such 
as TNF and IL-1, are thought to play in the pathogenesis of 
RA, the genetic variation of these cytokines and their actual 
presence in the joint, it is possible that polymorphisms regu-
lating cytokine production affect the natural course of the 
disease [12]. A number of polymorphisms with possible 
functional phenotypes have recently been identified, most 
often in the promoter regions for several of the cytokines 
(Table 1); these are thought to be important in maintaining 
the balance between proinflammatory and anti-inflammatory 
cytokines. 
1. TNF 
  One of the molecules shown to play a key role in patho-
genesis of RA is the proinflammatory cytokine TNF. This 
cytokine belongs to a family of proteins involved in immune 
regulation and programmed cell death. In patients with RA, 
TNF levels are chronically elevated in the blood and, more 
specifically, in the joints [13]. The functions of TNF are me-
diated by two distinct TNF receptors, TNFRSF1A and 
TNFRSF1B, which exist both as monomers on cell surfaces 
and in soluble forms [14]. TNF has been shown to be in-
volved in the stimulation of cytokine production, enhancing 
the expression of adhesion molecules, and in neutrophil acti-
vation. TNF is also a co-stimulator of T-cell activation and 
antibody production by B cells [15]. TNF, therefore, con-
tributes to the regulation of normal homeostasis as well as 
playing an important role in inflammation. Approximately 
60% of the variation in TNF production may be genetically 
determined, indicating a strong genetic influence on the pro-
duction of cytokines [16]. These observations, in conjunction 
with the localization of the TNF gene on chromosome 6 
within the MHC class III region between the HLA-B and 
HLA-DR genes [17], prompted speculation about the exis-
tence of functionally-relevant polymorphisms in the TNF 
gene. As a consequence, the TNF gene has received consid-
erable attention as a candidate disease-associated gene in 
RA.  
  Within the TNF gene, most of the single nucleotide po-
lymorphisms (SNPs) have been located to the promoter re-
gion (Fig. 1). The first polymorphism identified is a guanine 
(G) to adenine (A) transition at position -308. The uncom-
mon A allele is strongly associated with the HLA-A1-B8-
DR3-DQ2 haplotype [18], and is also associated with both 
autoimmune diseases and the high TNF producer phenotype 
[19]. This allele could facilitate deregulation of the cytokine 
network, affecting the pathology of RA [16].  
  Studies of polymorphism at position -238 showed either 
a G or the less common A allele at this site. Of the three pos-
sible genotypes on the two chromosomes, GG and GA are 
the most common. The GG genotype appears to be associ-
ated with more severe articular erosions; the cartilage of 
those patients with the GA genotype deteriorated more 
slowly [20]. Studies have shown a similar association with 
the site +489, where the GG genotype is also associated with 
more severe erosive disease [16].  
  These polymorphisms, as well as others within this gene, 
such as -1031 T/C, -863 C/A, -857 C/T or +1304 G/A, may 
contribute to susceptibility to RA by increasing TNF- pro-
duction [21-24]. They take part in several haplotypes be-
cause of the large number of potentially relevant polymor-
phisms and the complex patterns of linkage disequilibrium 
that occurs in the MHC region [25]. 
  A SNP has also been described in exon 6 of the TNF- 
receptor type 2 (TNFRSF1B). This polymorphism consists 
of a single base substitution at codon 196 (ATG to AGG) 
leading to a nonconservative amino acid change (methionine 
to arginine). The 196G allele may increase IL-6 production 
more than the 196T allele. The 196G allele may also affect 
membrane receptor shedding and/or ligand binding [26]. 
  DNA microsatellites in the TNF locus have also been 
described. These repeated sequences of bases A and T found 
in the non-coding regions of DNA serve as genetic markers 
when they occur in linkage disequilibrium with a nearby 
functional polymorphism [27]. The TNF locus has five mi-
crosatellites (TNFa through TNFe) based on the number of 
repeated sequences [28]. In vitro studies suggest that TNFd 
and TNFa2 are associated with high levels of TNF- while 
TNFa6 correlates with low levels of TNF- [28]. Some mi-
crosatellite haplotypes have been associated with increased 
susceptibility to RA, specifically TNFa6;b5;c1;d3;e3 [29]. 
2. IL-1 
  In addition to TNF, IL-1 is another cytokine considered 
to be a major contributor to chronic destructive arthritis. It is 
generally accepted that arthritis can be induced in mice by 
injection of recombinant cytokines (TNF or IL-1) into the 
knee joint [30]. The biological activity of IL-1 depends on 
the balance between two proinflammatory cytokines (IL-1 
and IL-1) and a related anti-inflammatory protein, the IL-1 
receptor antagonist (IL-1RA). The latter protein blocks the 
binding of IL-1 and IL-1 to the receptor. IL-1 is a particu-
larly potent cytokine because it induces the suppression of 
matrix synthesis by the chondrocytes and the release of ac-
tive aggrecanase, the dominant enzyme responsible for pro-
teoglycan loss [30]. 
  The genes encoding these three proteins (IL-1, IL-1 
and IL-1RA) have been mapped to a 430 kb region on chro-
mosome 2 [31]. SNPs and other variations have been identi-
fied in each of the genes, which, together with linkage dise-Pharmacogenomics in Rheumatoid Arthritis  Current Genomics, 2008, Vol. 9, No. 6    383 
quilibrium across the region, lead to the presence of common 
haplotypes in the population [32]. Among polymorphisms of 
particular interest are (i) biallellic SNPs in the IL-1 gene at 
position -889 C/T [33] and in exon 5 at +4845 G/T [34], (ii) 
in the IL-1 gene at position -511 C/T [35] and in exon 5 at 
+3953 C/T [36], (iii) in the IL-1RA gene at position +2018 
C/T in exon 2 [37], and a (iv) penta-allelic polymorphic site 
in intron 2 containing variable numbers of an 86-bp tandem 
repeat (VNTR) sequence. Studies have reported an associa-
tion with the presence of the rarer alleles at IL-1 (+4845) or 
IL-1 (+3953) and an increased susceptibility to RA [38], as 
well as an increased severity of joint destruction [39]. Other 
studies have related IL-1 (-889), IL-1 (+4845), IL-1 
(+3953) and IL-1RA VNTR allele 2 polymorphisms to al-
tered IL-1 production [40-42]. It has also been suggested that 
the genotype at IL-1 may influence IL-1RA levels [40]. IL-
1RA +2018 C/T gene polymorphism may also have a pro-
inflammatory effect [43]. 
Table 1.  Gene Polymorphisms in Rheumatoid Arthritis (RA) 
Gene Symbol  Polymorphism Position  Alleles  Possible Effect of Polymorphism  References 
TNF  +1304 
G 
A 
May contribute to the susceptibility to RA / Possible linkage disequilibrium  [22] 
  +489 
G 
A 
More severe erosive disease  [16] 
  -238 
G 
A 
More severe articular erosions 
Less severe articular erosions 
[20] 
  -308 
G 
A 
Normal production of TNF 
Up-regulation of TNF production 
[19, 18] 
  -857 
C 
T 
May contribute to the susceptibility to RA / High TNF production  [23] 
 -863 
C 
A 
May contribute to the susceptibility to RA / High TNF production  [21] 
 -1031 
T 
C 
May contribute to the susceptibility to RA / High TNF production  [22, 24] 
  TNFa6;b5;c1;d3;e3  Increased susceptibility to RA  [29] 
TNFRSF1B codon  196 
T 
G 
More effective in increasing IL-6 production  [26] 
IL-1  IL-1 -889 
C 
T 
Altered production of IL-1 [42] 
 
IL-1 +4845  
(exon 5) 
G 
T 
Altered production of IL-1 / Increased susceptibility to RA  [34, 38, 41] 
 IL-1 -511 
C 
T 
Altered production of IL-1RA  [40] 
 
IL-1 +3953 
(exon 5) 
C 
T 
Altered production of IL-1RA / Severe joint destruction  [40, 41, 39] 
 
IL-1RA +2018 
(exon2) 
C 
T 
Possible pro-inflammatory effect  [43] 
IL-6  -174 
G 
C 
Reduced production of IL-6  [49] 
  -622 
G 
A 
Reduced production of IL-6  [48] 
IL-10  -1082 
G 
A 
Up-regulation of IL-10 production in lymphocytes 
Lower expression levels of IL-10 / Associated with RA in women 
[12] 
[52, 54] 
  -819 
T 
C 
Lower expression levels of IL-10 / Autoimmune manifestations  [52, 53] 
  -592 
A 
C 
Lower expression levels of IL-10 / Autoimmune manifestations  [52, 53] 
HLA  Specific shared epitope alleles (HLA-DR)  May increase susceptibility to and severity of RA  [8-10] 
TNF- = tumor necrosis factor-; TNFRSF 1B = TNFreceptor; IL-1 = interleukin-1; IL-6 = interleukin-6; IL-1RA = IL-1 receptor antagonist; HLA = Human Leukocyte Antigen. 384    Current Genomics, 2008, Vol. 9, No. 6  Rego-Pérez et al. 
3. IL-6 
  IL-6 is another pleiotropic cytokine with a wide range of 
biological activities, including regulation of immune re-
sponse, inflammation, haematopoiesis and bone metabolism 
[44]. The constitutive overproduction of IL-6 is thought to 
play a pathogenic role in RA. Serum IL-6 levels are reported 
to correlate with disease activity and radiographic joint dam-
age [45]. However, other findings suggest that IL-6 may act 
as an anti-inflammatory mediator [46]. IL-6 has been ob-
served to augment circulating levels of IL-1RA and soluble 
TNF receptor, both of which could have important anti-
inflammatory effects by suppressing the action of IL-1 and 
TNF [47]. 
  IL-6 promoter polymorphisms have also been described. 
The G/C transversion at position -174 and the G/A transition 
at position -622 are the most analyzed. These two polymor-
phisms are in complete linkage disequilibrium [48]. The -
174 position polymorphism has been shown to affect IL-6 
levels and has been associated with systemic juvenile 
chronic arthritis [49],  although more recent data appear to 
rule out any important role of these polymorphisms in sus-
ceptibility to RA [48,50].  
4. IL-10 
  IL-10 is another cytokine that mediates down-regulation 
of the inflammatory response. Specifically, IL-10 acts as a 
negative autocrine regulator of TNF- and other proinflam-
matory cytokines [51]. Allelic polymorphisms in the gene 
for IL-10, which is located on chromosome 1, affect the re-
spective levels of cytokine produced. Thus, allelic mutations 
at positions -1082 G to A, -819 T to C and -592 A to C may 
result in an ACC haplotype associated with lower expression 
levels of IL-10 [52]. These allelic variations are also corre-
lated with autoimmune manifestations [53], in particular, the 
-1082AA genotype is associated with RA in women [54]. 
However, these IL-10 promoter polymorphisms were not 
important for development or severity of RA in Colombian 
population [55]. In contrast, the IL-10 -1082GG genotype is 
associated with an up-regulation of IL-10 production in lym-
phocytes [12]. 
PHARMACOGENETICS OF ANTIRHEUMATIC 
DRUGS 
Disease Modifying Antirheumatic Drugs (DMARDs) in 
RA 
  This class of drugs potentially reduces or prevents joint 
damage and preserves joint integrity and function by affect-
ing the immune system. However, the outcome of treatment 
with these drugs in RA patients is quite variable and unpre-
dictable. The cause for differences in efficacy and occur-
rence of adverse drug reactions may be genetic variation in 
drug metabolism among individuals.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Schematic representation of the tumor necrosis factor- (TNF-) gene, showing some of the most relevant single nucleotide poly-
morphisms (SNPs). The horizontal arrows in the middle row indicate the transcriptional orientation of the TNF and lymphotoxin (LT) genes. 
Diagonally highlighted regions in exons 1 and 4 indicate the untranslated regions (UTRs). Pharmacogenomics in Rheumatoid Arthritis  Current Genomics, 2008, Vol. 9, No. 6    385 
  Among the DMARDs that have the most potential for use 
in “tailor-made drug therapy” for RA patients are metho- 
trexate, sulfasalazine and azathioprine. 
1. Methotrexate 
  Methotrexate (MTX) is one of the most widely used 
DMARDs for treatment of RA. The principal pharmacologi-
cal effect of MTX is thought to be antagonism for folate. 
MTX enters the cell through reduced folate carrier-1 (RFC-
1) and is intracellularly converted to MTX polyglutamates. 
Polyglutamation of MTX enhances the intracellular retention 
of MTX and promotes the inhibition of de novo purine syn-
thesis along with the buildup of adenosine, a potent anti-
inflammatory agent [56]. MTX directly inhibits several en-
zymes of the folate pathway, including dihydrofolate reduc-
tase (DHFR), thymidilate syntase (TYMS) and 5-amino- 
imidazole-4-carboxamide ribonucleotide (AICAR) trans-
formylase (ATIC). Other folate enzymes are not directly 
inhibited by MTX, such as methylenetetrahydrofolate reduc-
tase (MTHFR), but their expression level may contribute to 
the antifolate effects of MTX [57]. Several polymorphisms 
in genes related to MTX transport across the cell membrane 
and the enzymes involved in the cellular metabolic pathway 
of MTX have been described (Table 2). 
  Polymorphisms influencing MTX transport across the 
cell membrane include the reduced folate carrier 1 (RFC-1) 
G80A and adenosine triphospate-binding cassette B1 
(ABCB1) C3435T. ABCB1 encodes a membrane transporter 
(P-glycoprotein) implicated in the disposition and bioavail-
ability of several drugs. Genetic variations in these genes 
would affect the response to MTX in RA because both genes 
are involved in MTX transport. Individuals having the RFC 
80A/A genotype have a greater response to MTX than pa-
tients with the wild-type allele (80G/G) [58]. Patients with 
the ABCB1 3435C/C and 3435C/T genotypes are at greater 
risk for active RA compared with patients with the 3435T/T 
genotype, who are better MTX responders [59]. 
  Among the gene polymorphisms that influence metabolic 
enzymes in the cellular pathway of MTX, of particular note 
are two SNPs associated with the most studied gene in the 
MTX cellular pathway, that for methylenetetrahydrofolate 
reductase (MTHFR). This enzyme is very important in re-
generation of reduced folate. The MTHFR C677T polymor-
phism results in a thermolabile variant of MTHFR with de-
creased enzyme activity [60]. A wide range of clinical ef-
fects is associated with this polymorphism, such as increased 
gastrointestinal side effects [61], increased hepatic toxicity 
[62] and overall adverse events [63]. A recent report shows 
that carriers of the MTHFR 677TT genotype are less likely 
to respond to MTX than those with alternate genotypes [64]; 
however, other authors have not found any effects on toxic-
ity and efficacy [65, 66]. The A1298C polymorphism also 
results in decreased MTHFR activity and exhibits other dis-
crepancies in its clinical effects. Some studies of carriers of 
this allele suggest increased MTX efficacy [62,63], increased 
susceptibility to RA [65] and increased risk of toxicity 
[64,67,68]; however, another study did not find any effects 
on efficacy and toxicity [66]. 
  The genes for thymidylate synthase (TYMS) and amino-
imidazole carboxamide ribonucleotide transformylase (ATIC) 
are also related to the cellular pathway of MTX. In fact, 
these enzymes are targets of MTX. TYMS is a key enzyme 
Table 2.  Pharmacogenetics of Methotrexate (MTX) in Rheumatoid Arthritis (RA) 
Gene Symbol  Polymorphism  Effect of Polymorphism  Pharmacogenetics  References 
RFC1  G80A  Increased MTX entry into cell  Increased response to MTX  [58] 
ABCB1 C3435T  Involved in MTX transport  Increased response to MTX  [59] 
Increased  gastrointestinal side effects and 
increased hepatic toxicity 
[61, 62] 
Overall adverse events  [63] 
C677T 
Thermolabile variant of MTHFR enzyme  
 with decreased enzyme activity 
No effects on toxicity or efficacy  [65, 66] 
Increased MTX efficacy  [62, 63] 
Increased susceptibility to RA  [65] 
No effects on toxicity or efficacy  [64, 66] 
MTHFR 
A1298C Decreased  MTHFR  activity 
Increased risk of toxicity  [64, 67, 68] 
5´UTR 28 bp repeat  Increased mRNA expression and enzyme activity  Decreased MTX efficacy  [66] 
TYMS 
3´UTR 6bp deletion  Decreased mRNA stability and expression  Increased MTX efficacy [66] 
ATIC  C347G  AICAR accumulation and increased adenosine 
In combination with double-repeat allele in 
TYMS or the RFC1 G80A SNP seems to 
correlate with an increased response to MTX 
[73] 
RFC1 = reduced folate carrier 1; ABCB1 = adenosine triphospate-binding cassette B1; MTHFR = methylenetetrahydrofolate reductase; TYMS = thymidylate synthase; ATIC = 
aminoimidazole carboxamide ribonucleotide transformylase; SNP = single nucleotide pohymorphism. 386    Current Genomics, 2008, Vol. 9, No. 6  Rego-Pérez et al. 
in de novo thymidylate synthesis, converting deoxyuridine 
monophosphate (dUMP) to deoxythymidine monophosphate 
(dTMP). This enzyme is inhibited by polyglutamated MTX. 
A polymorphic tandem repeat sequence has been identified 
in the 5´-untranslated region (5´-UTR) of the TYMS gene, 
with a variable number of 28-bp repeat elements [69]; the 
higher the number of repeat elements, the higher the mRNA 
expression and enzyme activity [70] and the less the efficacy 
of MTX [66]. Another polymorphism, consisting of a 6-bp 
deletion of the sequence TTAAAG at nucleotide 1494 in the 
3´-UTR of TYMS, has been described [71]. This deletion 
may be associated with decreased TYMS mRNA stability 
and expression [72], thereby increasing MTX efficacy [66]. 
  ATIC converts aminoimidazole carboxamide ribonucleo-
tide (AICAR) to 10-formyl AICAR. ATIC is directly inhib-
ited by MTX, leading to accumulation of both AICAR and 
adenosine, an anti-inflammatory purine. A previous study 
determined that homozygosity for the C347G polymorphism 
in ATIC, the double-repeat allele in TYMS or the RFC1 
G80A SNP appeared to correlate with increased MTX re-
sponse [73]. 
  Polymorphisms have been described in other genes in the 
MTX pathway, such as -glutamyl hydrolase (GGH), DHFR 
or methionine synthase (MS), although their functional and 
clinical significance remain unknown. 
2. Sulfasalazine 
  Sulfasalazine (SASP) is another DMARD commonly 
used to treat RA. However, the use of SASP is limited by the 
occurrence of adverse effects in some individuals [74]. After 
oral intake, SASP is cleaved by intestinal bacteria into 5-
amino salicyclic acid and sulfapyridine. Sulfapyridine is then 
metabolized in the liver by acetylation. The N-acetyltrans- 
ferase 2 (NAT2) gene, located on chromosome 8p22, en-
codes the enzyme involved in the acetylation of sulfapyri-
dine and can be polymorphic. Polymorphisms in the NAT2 
gene (Table 3), which influence the slow versus fast acetyla-
tor status of individuals, are the direct determinant of acety-
lator status. Slow acetylators are more prone to toxicities 
from SASP compared to fast acetylators [75].  
  The wild-type NAT2*4 allele encodes the rapid acetyla-
tor status; though there are a large number of NAT2 variants, 
those for NAT2*5A, NAT2*5B, NAT2*5C, NAT2*6 and 
NAT2*7, which consist of several SNP combinations in 
exon 2 of the gene, are the most common variants that en-
code the slow acetylator status by means of decreased activ-
ity of the NAT2 enzyme. Because of the slow acetylation, 
these variants are associated with increased concentrations of 
toxic SASP intermediates [76,77]. 
  The acetylator status of an individual, which appears to 
be influenced by NAT2 polymorphisms, seems to be impor-
tant in determining the risk of toxicity from SASP. Thus, 
assays to prospectively identify the NAT2 genotype in pa-
tients before SASP administration will be powerful tools in 
clinical practice for averting SASP toxicity [78]. 
3. Azathioprine 
  Azathioprine (AZA) is widely used to treat malignancies, 
rheumatic diseases and solid organ transplant rejection. AZA 
is now used less frequently for treatment of RA because of 
the changes in the treatment system along with the develop-
ment of other DMARDs [77]. Thiopurine methyltransferase 
(TPMT) is one of major enzymes involved in the metabolism 
of AZA. Population studies have established that the activity 
of TPMT in erythrocytes is trimodal: approximately 90% of 
the population has high activity, 10% has intermediate activ-
ity and 0.3% has low or no activity [79].  
  Three allelic variants of the TPMT gene: TPMT*2 
(G238C), TPMT*3A (G460A and A719G), TPMT*3C 
(A719G) (Table 4) account for 60-95% of persons with low 
Table 3.  Pharmacogenetics of Sulfasalazine (SASP) in Rheumatoid Arthritis (RA) 
Gene Symbol  Polymorphism  Effect of Polymorphism  Pharmacogenetics  References 
NAT2  NAT2*4  Increased activity of NAT2 enzyme  Decreased concentrations of SASP intermediates  [75] 
   (wildtype)  (fast acetylator status)  Less prone to toxicities from SASP    
   NAT2*5A  Decreased activity of NAT2 enzyme  Increased concentrations of SASP intermediates  [76, 77] 
   T341C,C481T  (slow acetylator status)  More prone to toxicities from SASP    
   NAT2*5B  Decreased activity of NAT2 enzyme  Increased concentrations of SASP intermediates  [76, 77] 
   T341C,C481T,A803G  (slow acetylator status)  More prone to toxicities from SASP    
   NAT2*5C  Decreased activity of NAT2 enzyme  Increased concentrations of SASP intermediates  [76, 77] 
   T341C,A803G  (slow acetylator status)  More prone to toxicities from SASP    
   NAT2*6  Decreased activity of NAT2 enzyme  Increased concentrations of SASP intermediates  [76, 77] 
   C282T,G590A  (slow acetylator status)  More prone to toxicities from SASP    
   NAT2*7  Decreased activity of NAT2 enzyme  Increased concentrations of SASP intermediates  [76, 77] 
   C282T,G857A  (slow acetylator status)  More prone to toxicities from SASP    
NAT2 = N-acetyltransferase 2. Pharmacogenomics in Rheumatoid Arthritis  Current Genomics, 2008, Vol. 9, No. 6    387 
or intermediate TPMT activity [80]. Clinically, these poly-
morphisms are associated with hematological and gastroin-
testinal toxicity [81]. Thus, TPMT genotyping would be 
helpful for predicting AZA toxicity. 
Biological Agents in RA 
  The introduction of biological agents has dramatically 
improved the treatment of RA. These agents not only reduce 
the symptoms and signs of the disease, they also slow down 
the radiographic progression of disease [82]. However, these 
therapies are substantially more expensive than traditional 
DMARDs and are not effective in all patients [83]. In fact, 
there is consistent evidence that 25% to 30% of RA patients 
fail to respond [84]. The early identification of patients who 
will respond positively to these drugs would greatly help to 
establish a cost-effective treatment profile for the use of 
these molecules [85]. 
  Intensive studies on the TNF and IL-1 driven inflamma-
tion processes have led to the development of cytokine 
blockers for RA treatment. Three TNF blockers are currently 
approved by the Food & Drug Administration (FDA) for the 
treatment of RA: Etanercept, Infliximab  and Adalimumab. 
These blockers are derived from either a recombinant TNF 
receptor, TNFRSF1B in the case of Etanercept, or an anti-
TNF- monoclonal antibody for Infliximab and Adalimu-
mab. The molecular mechanism of these TNF blockers, al-
though quite different, involves inhibition of the binding of 
TNF to cell surface TNF receptors, thereby blocking signal 
transduction pathways induced or regulated by TNF. Al-
though anti-TNF- neutralizing therapy can be highly effec-
tive in reducing symptoms and signs of RA, not all patients 
show the same degree of response in disease progression 
[86]. It has been suggested that variability in the promoter 
and coding regions of the TNF- gene may modulate the 
magnitude of the secretory response of this cytokine [87]. 
  The fourth biological agent approved by the FDA for the 
treatment of RA is Anakinra, a recombinant form of IL-1RA 
whose molecular mechanism was explained above. 
  The drugs with the potential for use in “tailor-made drug 
therapy” for RA patients share problems relating to efficacy 
and toxicity. An increased risk of lymphoma is one example 
of the toxicity associated with these drugs. However, we 
must take into account the fact that patients with severe RA 
have approximately a two-fold increased risk of lymphoma. 
Some of this increased risk reflects an increase in Epstein-
virus-associated lymphomas. This may be related to the ele-
vated Epstein-Barr virus load found in RA patients and may 
reflect the subtle impairment of antiviral immunity in this 
group of patients [88]. 
1. Etanercept 
  Etanercept is a dimeric fusion protein that joins the hu-
man p75 TNF receptor to the FC domain of human IgG1 
(Fig.  2a). This drug is made exclusively of human amino 
acidic sequences and has 934 amino acids. 
  The effectiveness of Etanercept for the treatment of RA, 
and early RA, has been proven both in monotherapy or com-
bined with Methotrexate. The radiologically-assessed pro-
gression of joint degeneration decreases significantly when 
this drug is used for more than 24 months. Treatment with 
Etanercept alone shows significantly better clinical results 
than treatment with MTX alone. 
  Unfortunately, opportunistic infections, including tuber-
culosis, cardiac insufficiency and lymphoma, have been de-
scribed in some patients treated with Etanercept. This risk in- 
creases if corticosteroids or other immunosupressive agents, 
such as MTX, are given concurrently. An association with 
demyelinating diseases has also been suggested [89]. 
2. Infliximab 
  Infliximab is a monoclonal antibody that binds to and 
neutralizes the activity of TNF-. It is a mouse/human chi-
mera that joins the variable regions of a mouse antibody to 
the constant region of human IgG1 (Fig. 2b). This drug was 
the first TNF blocker used in the treatment of RA and dem-
onstrated the importance of TNF- in the pathology of RA. 
  Important benefits of Infliximab include improved qual-
ity of life, prevention of structural articular damage and, pos-
sibly, bone repair. This drug has also been successfully used, 
both alone and combined with MTX, in treating other dis-
eases such as Crohn´s, ankylosing spondylitis and psoriatic 
arthritis. 
  Regrettably, Infliximab shares some of the same prob-
lems as Etanercept, including infusion reactions, opportunis-
tic infections, tuberculosis and increased risk of lymphoma 
Table 4.  Pharmacogenetics of Azathioprine (AZA) in Rheumatoid Arthritis (RA) 
Gene Symbol  Polymorphism  Effect of Polymorphism  Pharmacogenetics  References 
TPMT  TPMT*2  Low to intermediate activity of TPMT  Hematological and gastrointestinal toxicity  [81] 
   G238C  Decreased methylation of AZA       
   TPMT*3A  Low to intermediate activity of TPMT  Hematological and gastrointestinal toxicity  [81] 
   G460A, A719G  Decreased methylation of AZA       
   TPMT*3C  Low to intermediate activity of TPMT  Hematological and gastrointestinal toxicity  [81] 
   A719G  Decreased methylation of AZA       
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[90]. Demyelinating processes, cardiac insufficiency and 
autoimmune disorders associated with Infliximab treatment 
have also been described. 
3. Adalimumab 
  Adalimumab is a fully human IgG1 monoclonal antibody 
whose molecular mechanism is similar to that of Infliximab. 
It binds to circulating and cell-surface TNF- and blocks the 
interaction of TNF- with the cell surface TNF receptors p55 
and p75 (Fig. 2c). Adalimumab also modulates the biological 
responses induced by TNF and reduces levels of IL-6 and 
MMPs (MMP-1 and MMP-3) [91]. 
  Adalimumab is utilized either as a monotherapy or with 
MTX. An outstanding benefit of Adalimumab is that it inhib-
its the progression of the structural articular damage in long-
term RA patients who have not experienced satisfactory re-
sponse to DMARDs. 
  The toxic effects associated with the use of Adalimumab 
include the same problems seen with Etanercept and Inflixi-
mab: opportunistic infections, tuberculosis, demyelinating 
processes, autoimmune disorders and cardiac insufficiency. 
4. Anakinra 
  Anakinra is a recombinant form of human IL-1RA that 
acts as an antagonist to the biological activity of IL-1 by 
competitively inhibiting the binding of IL-1 to its cell mem-
brane receptor, thus blocking cell signaling (Fig. 2d). Its 
effectiveness in treating RA patients has been investigated 
either alone or combined with Etanercept, MTX, or other 
DMARDs [92,93,94]. Therapy with Anakinra in combina-
tion with Etanercept has not shown a clinical advantage and, 
at present, is contraindicated because of an increase in op-
portunistic infections. 
  The inhibition of the progression of structural damage in 
RA is an important benefit of Anakinra. However, an ad-
verse reaction at the injection site is the major disadvantage 
of this drug. Pneumonias and cutaneous infections have also 
been described [94]. 
Pharmacogenetics of Biological Agents 
  Several studies have correlated the response to these bio-
logical agents with some of the gene polymorphisms de-
scribed in this review (Table 5). Extended haplotypes span-
ning from HLA-DRB1 to the TNF region influence Etaner-
cept response in Caucasian patients [95]. In the same study, 
the authors show that patients with two copies of the HLA-
DRB1 shared epitope alleles had an improved response to 
Etanercept compared to patients without the allele or with 
one copy of the allele. Because of the large number of genes 
with roles in immune system function and regulation in the 
HLA region and the extensive linkage disequilibrium seen in 
this region, it is likely that a number of other genes influence 
treatment response [96].  
  In an extensive study, 78 patients treated with Infliximab 
were genotyped for HLA-DRB1, HLA-DQA1 and HLA-
DQB1 alleles, a trinucleotide repeat polymorphism within 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Molecular mechanism of biologic therapies: A) The tumor necrosis factor- (TNF-) blocker, Etanercept. B) The tumor necrosis 
factor- (TNF-) blocker, Infliximab. C) The tumor necrosis factor- (TNF-) blocker, Adalimumab. D) The interleukin-1 (IL-1) blocker, 
Anakinra, a recombinant form of the human IL-1 receptor antagonist (IL-1RA). Pharmacogenomics in Rheumatoid Arthritis  Current Genomics, 2008, Vol. 9, No. 6    389 
the MHC class I chain-related gene A (MICA), and TNF 
microsatellites a through e, D6S273, BAT2 and D6S2223. 
The authors concluded that the D6S273_4/ BAT2_2 micro-
satellite haplotype pairs occurred significantly more often in 
responders than non-responders. Similarly, the frequency of 
the TNFa11;b4 haplotype, a marker usually found in context 
with D6S273_4/ BAT2_2, was increased and that of the 
D6S273_3 allele was decreased in responders [11]. These 
results led the authors to speculate that these markers occur 
on the same haplotype that carries an unknown “response 
gene.” 
  In other studies, a correlation between both the TNF- -
308G [12] and TNF- -857T polymorphisms and good re-
sponse to Etanercept has been shown [97]. Other authors 
have studied the response to Etanercept or Infliximab in pa-
tients with severe RA, characterized by non-responsiveness 
to MTX, in combination with other DMARDs. Those pa-
tients with the TNFRSFB 196TT genotype had a higher level 
of responsiveness to anti-TNF therapy over 24 weeks than 
did patients with the TG/TG genotype. Based on these re-
sults, the 196TT genotype correlates with a higher response 
to anti-TNF therapy in RA, while the presence of the G allele 
correlates with a reduced response [98]. 
  The combination of TNF -308 G/G with IL-10 -1082G/G 
genotypes (patients with lower inflammatory response) also 
showed a better response to Etanercept. Thus, Etanercept 
appears to be more effective in patients carrying a genotype 
encoding for a lower inflammatory response [12]. Another 
study showed that IL-10 promoter microsatellite polymor-
phisms are associated with improved response to long term 
treatment with Etanercept [99]. 
  Pharmacogenetic studies on the effectiveness of Inflixi-
mab have also been performed. The -308 G/A SNP in the 
TNF promoter region [100,101,102] was found to influence 
the response to Infliximab; those with the G/G genotype 
were better responders. Some authors speculate that the TNF 
-308 polymorphism influences the response to Infliximab 
Table 5.  Pharmacogenetics of Biological Agents in Rheumatoid Arthritis (RA) 
Gene 
Symbol 
Polymorphism 
Position  Alleles  Possible Effect of Polymorphism  Pharmacogenetics  References 
+489 
G 
A 
More severe erosive disease  No effect on response to Etanercept  [95] 
-238 
G 
A 
More severe articular erosions 
Less severe articular erosions 
No effect on response to Etanercept  [95] 
-308 
G 
A 
Normal production of TNF 
Up-regulation of TNF production 
Increased response to Infliximab  [100, 101] 
-857 
C 
T 
Susceptibility to RA / High TNF production  Increased response to  Etanercept  [97] 
TNF 
TNFa11;b4 haplotype 
Influence production of TNF / Found  
with D6S273_4/BAT2_2 
Increased response to Infliximab  [11] 
TNFRSF1B codon  196 
T 
G 
More effective in increasing IL-6 production  Increased response to anti-TNF therapy  [98] 
IL-1 
IL-1 +4845 
(exon 5) 
G 
T 
Altered production of IL-1 / Increased 
susceptibility to RA 
Increased response to Anakinra  [104] 
-1082 
G 
A 
Up-regulation of IL-10 production  
in lymphocytes 
Lower expression levels of IL-10 /  
Associated with  RA in women 
Increased response to Etanercept in 
combination with TNF -308G/G 
-819 
T 
C 
Lower expression levels of IL-10 /  
Autoimmune manifestations  Patients with low inflammatory haplotype 
IL-10 
-592 
A 
C 
Lower expression levels of IL-10 /  
Autoimmune manifestations  are better Etanercept responders 
[12] 
Specific shared 
epitope alleles (HLA-DR) 
May increase susceptibility to and 
 severity of RA 
Specific HLA-DRB1 alleles and haplotypes 
markers of better response to Etanercept 
[95] 
HLA 
HLA microsatelites 
BAT2,D6S273,D6S2223 
Haplotype may carry "response gene" 
D6S273_4/BAT2_2 haplotype correlates 
with increased response to Infliximab 
[11] 
TNF- = tumor necrosis factor-; TNFRSF1B = TNFreceptor; IL-1 = interleukin-1; IL-10 = interleukin-10. 390    Current Genomics, 2008, Vol. 9, No. 6  Rego-Pérez et al. 
through its effects on circulating TNF levels [99]. The pres-
ence of the A allele (high TNF production) would correlate 
with a poorer response to Infliximab. However, other studies 
of TNF -308 G/A polymorphism reported no association 
with response to Infliximab [98,11]. In the same way, a 
study carried out by our group in 113 RA subjects showed 
that TNF- gene promoter polymorphisms, G-308A and G-
238A, and the SE and DR3 alleles do not correlate with the 
response to Infliximab after 30 weeks quantified by im-
provement of DAS 28 [103]. 
  To our knowledge, the only pharmacogenetic study of the 
responsiveness to Anakinra showed a highly significant as-
sociation between the presence of the rarer T allele at IL-1 
(+4845) and response to Anakinra [104].  
CONCLUSIONS 
  In summary, the response to therapy is probably partially 
determined by the genetic makeup of the individual. As 
stated previously, RA is a disease defined by well accepted 
criteria [105], but its clinical features and the molecular 
pathways involved are heterogeneous [106]. Therefore, the 
response to different treatments varies considerably among 
individual patients. With the development of a variety of 
costly new drugs and a lack of complete information on side 
effects, such as susceptibility to infection, the need for ge-
netic markers prognostic for treatment response is increasing 
[107]. These genetic markers may lie in some of the genes 
described above, genes encoding the proteins involved in the 
drug target, drug metabolism or disease pathogenesis [108]. 
In this sense, the results of a study by Lequerré et al. are of 
particular interest [109]. They obtained a gene profiling of 
41 mRNA transcripts suitable to predict the likely response 
to treatment with the combination of infliximab and MTX 
from peripheral blood mononuclear cells. An understanding 
of the genetic contribution to treatment success will become 
more and more relevant as therapies begin to target the key 
mechanisms of RA pathology [107]. 
  To date, many polymorphisms in TNF, TNFRSF1B, 
MHC class alleles and other cytokine genes have been de-
scribed; however their functional significance remains con-
troversial. Some studies have produced conflicting results; 
population stratification and linkage disequilibrium have 
been cited as potential causes for the inability to replicate 
results of genetic association studies [110]. It is possible that 
analysis of haplotypes in candidate regions, rather than indi-
vidual SNPs, may be a more productive approach. Because 
pharmacogenetics is a nascent field in which studies are just 
emerging, it is tempting to speculate that tailor-made cytoki-
nes or other specific molecule-directed treatments based on 
individual genotype will be applicable in the near future 
[30]. To achieve this individually-tailored approach to ther-
apy, large prospective studies involving multiple institutions 
will be required to obtain adequate patient numbers to de-
termine whether genetic variants of cytokines and other spe-
cific molecules contribute directly to either the pathophysi-
ology of RA or the response to treatments.  
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